Treatment‐related mortality ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with chronic lymphocytic leukaemia
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events – not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
1 finding from 1 review
Progression‐free survival · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy probably leads to lower progression‐free survival compared with observation (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment‐related mortality compared with observation (low certainty).
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment discontinuation compared with observation (low certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).
1 finding from 1 review
Return to normal activities (days) · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to fracture union · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain (medium term): using VAS (range 0 to 10); higher values indicate worse pain · adolescents and adults with acute fractures in tibia and femur
1 finding from 1 review
Delayed or non‐union (medium term) · adolescents and adults with acute fractures in tibia and femur
It is very uncertain whether extracorporeal shock wave therapy changes delayed or non‐union (medium term) compared with control (very low certainty).
1 finding from 1 review
Adverse events · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported quality of life · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quantitative functional improvement · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival
Hormone replacement therapy (HRT) may leads to lower overall survival compared with no HRT (low certainty).
1 finding from 1 review
Quality of life: 1. General quality of life
1 finding from 1 review
Progression‐free survival
Hormone replacement therapy (HRT) showed no clear difference in progression‐free survival compared with no HRT (low certainty).
1 finding from 1 review
Overall breast cancer incidence
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of breast cancer compared with no HRT (very low certainty).
1 finding from 1 review